Surface Triggered Self-Assembly of Fmoc-Tripeptide as an Antibacterial Coating
This article provides educational information about how these medications work together and what safety considerations apply when they are prescribed in combination
Therapy should be discontinued at least 2 months before a planned pregnancy due to the long washout period
Essential Baseline Assessment Depending on the treatment indication and medical history, a baseline assessment may include: Hemoglobin A1C Glucose Test Comprehensive Metabolic Panel Lipid Panel Complete Blood Count when clinically appropriate Kidney Profile or urine albumin-to-creatinine testing for relevant diabetes or kidney risk Early Follow-Up Follow-up may be considered after treatment initiation, dose escalation, or a clinically meaningful change in symptoms
Its also not available in the United States either
To date, it has been observed that the treatment with this kind of antitumor agents causes ROS generation, mitochondrial dysfunction (including frataxin deficiency, mitochondrial DNA damage and defective components of ETC), loss in antioxidant enzymes, ion channels disturbances and nerve tissue damage (protein carbonylation and lipid peroxidation) (Areti et al., 2013) have described in vitro and in vivo biochemical effects after exposure to high concentrations of oxaliplatin, including neuronal activation of the purinoreceptor subtype 7, ROS and NO production, lipid peroxidation, loss of mitochondrial transmembrane potential and further apoptosis via caspase 3 activation